Updated Overall Survival and Long-Term Transfusion Independence From the Phase 3 COMMANDS Trial in Erythropoiesis-Stimulating Agent-Naive Patients With Lower-Risk Myelodysplastic Syndromes

The presentation details long-term findings from the phase 3 COMMANDS trial comparing the efficacy and safety of luspatercept against epoetin alfa in transfusion-dependent patients with lower-risk myelodysplastic syndromes. The analysis evaluates critical secondary and post-hoc clinical outcomes between the treatment arms, such as overall survival trends, red blood cell transfusion independence, and sustained increases in hemoglobin levels. Additionally, it explores how various baseline parameters, patient demographics, molecular gene mutations, and safety profiles relate to the overall clinical benefit of each therapy.